CN114728005A - Bi853520在癌症治疗中的用途 - Google Patents

Bi853520在癌症治疗中的用途 Download PDF

Info

Publication number
CN114728005A
CN114728005A CN202080080643.5A CN202080080643A CN114728005A CN 114728005 A CN114728005 A CN 114728005A CN 202080080643 A CN202080080643 A CN 202080080643A CN 114728005 A CN114728005 A CN 114728005A
Authority
CN
China
Prior art keywords
kras
cancer
mutated
pharmaceutically acceptable
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080080643.5A
Other languages
English (en)
Inventor
王在琪
张江伟
江君
张宝袁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yingshi Biotechnology Nanjing Co ltd
Original Assignee
Yingshi Biotechnology Nanjing Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yingshi Biotechnology Nanjing Co ltd filed Critical Yingshi Biotechnology Nanjing Co ltd
Publication of CN114728005A publication Critical patent/CN114728005A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

涉及一种治疗发生KRAS突变的肿瘤的方法,所述方法使用化合物2‑氟‑5‑甲氧基‑4‑[(4‑(2‑甲基‑3‑氧代‑2,3‑二氢‑1H‑异吲哚‑4‑氧基)‑5‑三氟甲基‑嘧啶‑2‑基)氨基]‑N‑(1‑甲基‑哌啶‑4‑基)苯甲酰胺或其药学上可接受的盐,其可以单独给药,或者与KRAS抑制剂和/或MEK抑制剂联用。

Description

PCT国内申请,说明书已公开。

Claims (48)

  1. PCT国内申请,权利要求书已公开。
CN202080080643.5A 2019-11-28 2020-11-27 Bi853520在癌症治疗中的用途 Pending CN114728005A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2019111911398 2019-11-28
CN201911191139 2019-11-28
CN202011287049 2020-11-17
CN2020112870491 2020-11-17
PCT/CN2020/132244 WO2021104454A1 (zh) 2019-11-28 2020-11-27 Bi853520在癌症治疗中的用途

Publications (1)

Publication Number Publication Date
CN114728005A true CN114728005A (zh) 2022-07-08

Family

ID=76129165

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080080643.5A Pending CN114728005A (zh) 2019-11-28 2020-11-27 Bi853520在癌症治疗中的用途

Country Status (12)

Country Link
US (2) US20230000867A1 (zh)
EP (1) EP4066837A4 (zh)
JP (1) JP2023504460A (zh)
KR (1) KR20220107229A (zh)
CN (1) CN114728005A (zh)
AU (1) AU2020390236A1 (zh)
BR (1) BR112022010319A2 (zh)
CA (1) CA3159860A1 (zh)
MX (1) MX2022006402A (zh)
PE (1) PE20230180A1 (zh)
TW (1) TW202133852A (zh)
WO (1) WO2021104454A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021104454A1 (zh) * 2019-11-28 2021-06-03 应世生物科技(南京)有限公司 Bi853520在癌症治疗中的用途
CN116096713A (zh) * 2020-08-03 2023-05-09 应世生物科技(南京)有限公司 化合物的固体形式
WO2023003417A1 (ko) * 2021-07-22 2023-01-26 국립암센터 Kras 돌연변이 특이적 저해제 및 이를 포함하는 암 예방 또는 치료용 조성물
WO2023246869A1 (zh) 2022-06-24 2023-12-28 应世生物科技(南京)有限公司 治疗肿瘤的药物组合及用途
WO2024051679A1 (zh) * 2022-09-05 2024-03-14 应世生物科技(南京)有限公司 Fak抑制剂及egfr-tki的药物组合及用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104478865A (zh) * 2008-11-24 2015-04-01 贝林格尔·英格海姆国际有限公司 用于治疗例如癌症的疾病的取代的嘧啶
CN105530937A (zh) * 2013-03-13 2016-04-27 昂克希尔迪克斯有限公司 使用7-苄基-10-(2-甲基苄基)-2,6,7,8,9,10-六氢咪唑并[1,2-a]吡啶并[4,3-d]嘧啶-5(3h)-酮的联合疗法
CN108289892A (zh) * 2015-06-29 2018-07-17 维瑞斯特姆股份有限公司 治疗组合物、组合和使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2786696C (en) 2010-01-12 2021-05-25 Jill Detmer Oligonucleotides and methods for detecting pik3ca mutations
SG11201707127VA (en) 2015-03-06 2017-09-28 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
WO2020202005A1 (en) * 2019-04-02 2020-10-08 Inxmed (Shanghai) Co., Ltd. Combination of a fak kinase inhibitor and an agent targeting t-cell co-stimulatory receptors
JP2023503897A (ja) * 2019-11-18 2023-02-01 ▲應▼世生物科技(南京)有限公司 Nras変異を有する腫瘍を治療するための医薬品の調製におけるfak阻害剤の使用
WO2021104454A1 (zh) * 2019-11-28 2021-06-03 应世生物科技(南京)有限公司 Bi853520在癌症治疗中的用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104478865A (zh) * 2008-11-24 2015-04-01 贝林格尔·英格海姆国际有限公司 用于治疗例如癌症的疾病的取代的嘧啶
CN105530937A (zh) * 2013-03-13 2016-04-27 昂克希尔迪克斯有限公司 使用7-苄基-10-(2-甲基苄基)-2,6,7,8,9,10-六氢咪唑并[1,2-a]吡啶并[4,3-d]嘧啶-5(3h)-酮的联合疗法
CN108289892A (zh) * 2015-06-29 2018-07-17 维瑞斯特姆股份有限公司 治疗组合物、组合和使用方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GOVINDAN R等: "Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours", ANNALS OF ONCOLOGY, vol. 30, pages 163 *
HIRT等: "Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor pgenotype", ONCOGENESIS, vol. 7, no. 2, pages 4 *
NANA, FRANK ABOUBAKAR等: "Role of focal adhesion kinase in small-cell lung cancer and its potential as a therapeutic target", CANCERS, no. 11, pages 1 - 32 *
TOSHIHIKO DOI等: "Phase I study of the focal adhesion kinase inhibitor BI853520 in Japanese and Taiwanese Patients with advanced or metastatic solid tumor", TARGETED ONCOLOGY, no. 14, pages 57 *
YOON H等: "Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights", JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, vol. 63, no. 2, pages 114 - 128, XP055498179 *

Also Published As

Publication number Publication date
WO2021104454A1 (zh) 2021-06-03
JP2023504460A (ja) 2023-02-03
CA3159860A1 (en) 2021-06-03
EP4066837A4 (en) 2023-12-06
US20230372340A1 (en) 2023-11-23
EP4066837A1 (en) 2022-10-05
PE20230180A1 (es) 2023-02-01
AU2020390236A2 (en) 2022-07-21
AU2020390236A1 (en) 2022-07-14
BR112022010319A2 (pt) 2022-08-16
TW202133852A (zh) 2021-09-16
KR20220107229A (ko) 2022-08-02
MX2022006402A (es) 2022-06-24
US20230000867A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
CN114728005A (zh) Bi853520在癌症治疗中的用途
AU2018258663B2 (en) Treatment of HER2 positive cancers
US8426418B2 (en) Method to treat melanoma in BRAF inhibitor-resistant subjects
SG188207A1 (en) Combination anti - cancer therapy
KR20230157379A (ko) 소토라십 투약 요법
US20120083503A1 (en) Method for predicting therapeutic efficacy of chemotherapy on non-small-cell lung cancer
US20230346791A1 (en) Atr inhibitors for the treatment of cancer
CN117355306A (zh) 索托拉西布给药方案
Bhavani et al. Imatinib mesylate: Recent drug used in oncology
Haigentz et al. P2. 06-008 Phase 1/2 Study of Mocetinostat and Durvalumab (MEDI4736) in Patients with Advanced Solid Tumors and Non Small Cell Lung Cancer (NSCLC): Topic: Phase I/II Trials
WO2022191870A1 (en) Treating cancer in patient having co-occurring genetic alteration in fgfr2 and a cancer driver gene
WO2022238706A1 (en) Ret inhibitor for the treatment of ret altered medullary thyroid cancer or ret altered non-small cell lung cancer
TW202345846A (zh) 使用包含gdc-6036及gdc-0077之組合療法治療癌症
Dai et al. PB1949 CHRONIC MYELOID LEUKEMIA PATIENTS WITH BOTH HIGH TH1 AND HIGH CD8+ T-CELL LEVELS SHOW THE BETTER REMISSION, AND THE GOOD THERAPEUTIC RESPONSE ACCOMPANIES WITH THE HIGHER TH1 LEVEL
CA3230424A1 (en) Methods of treating cancer
KR20240004589A (ko) 소토라십 제형
EP2436762A1 (en) Method for prediction of therapeutic effect of chemotherapy employing expression level of dihydropyrimidine dehydrogenase gene as measure
CN116583540A (zh) 用于治疗her2癌症的组合疗法
EA044960B1 (ru) Лечение her2-положительных злокачественных новообразований

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40078043

Country of ref document: HK